Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: A matched study

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 102, Issue 2, 2002, Pages 179-183

  Del Gadillo, Juan C Barros ^a   Siebzehnrübl, Ernst ^a   Dittrich, Ralf ^b   Wildt, Ludwig ^a   Lang, Norbert ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

GnRH antagonist; ICSI; IVF; Outcome; Stimulation

Indexed keywords

CETRORELIX; HUMAN MENOPAUSAL GONADOTROPIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; MALE; OVARY HYPERSTIMULATION; OVULATION; PREGNANCY RATE; PRIORITY JOURNAL;

EID: 0037052598     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(01)00580-2     Document Type: Article

References (24)

1. The control of endogenous secretion of LH by gonadotropin-releasing hormone agonists during ovarian hyperstimulation for in vitro fertilization and embryo transfer
2. Influence of serum luteinizing hormone concentrations on ovulation, conception and early pregnancy loo in polycystic ovary syndrome
3. Comparative trial between an ultra-short and -long protocol of luteinizing-releasing hormone agonist for ovarian stimulation in in vitro fertilization
4. The use of gonadotropin-releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centres
5. ® and the LH-RH agonist buserelin
6. ® according to the multiple dose protocol: a prospective uncontrolled phase III study
7. Development and applications of luteinizing hormone-releasing hormone agonists in the treatment of infertility: an overview
8. ® ) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge
9. Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotropin-releasing hormone antagonist (Nal-Glu) during the late follicular phase
10. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women
11. ® during ovarian stimulation
12. ® in an in vitro fertilization embryo transfer program
13. ® ) on day 8 in vitro fertilization cycles: a pilot study
14. ® at different dosages
15. ® )
16. ® during controlled ovarian hyperstimulation
17. ® ) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg
18. Will GnRH antagonists provide new hope for patients considered difficult responders to GnRH agonist protocol?
19. LH-RH antagonist protocols in IVF do not lead to worse results than the long LH-RH agonist protocol
20. The effect of gonadotropin-releasing hormone (GnRH) agonist in the follicular phase on in vitro fertilization outcome in normo-ovulatory women
21. ® ) in women with tubal infertility
22. ® ) in controlled ovarian stimulation for assisted reproduction
23. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report